4.5 Article

Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo

Journal

CELLULAR IMMUNOLOGY
Volume 253, Issue 1-2, Pages 102-109

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2008.05.005

Keywords

CD40; CD40 ligand; IFN-gamma; colon cancer; proliferation

Ask authors/readers for more resources

CD40, a member of the tumor necrosis factor receptor superfamily, is widely expressed on various cell types. Some studies show that CD40 expression is related to several carcinomas, where its function remains largely unknown. This study investigated the expression of CD40 on colon cancer, and evaluated the effect of recombinant soluble human CD40L (rshCD40L) on colon cell lines. CD40 expression on the primary colon cancer samples was detected by immunohistochemistry. The expression of CD40 on colon cell lines was examined by reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry. To examine the effects of rshCD40L, the growth-inhibitory activity of rshCD40L on colon cancer cell was examined by MTT assay and the proportion of apoptotic tumor cells was examined in the TUNEL assay. Results showed that CD40 is expressed in human colon primary tumor. Expression of CD40 was elevated in 3 out of 4 colon cell lines examined by RT-PCR and flow cytometry. CD40 expression could be induced by interferon-gamma (IFN-gamma). CD40 ligand, rshCD40L, significantly inhibited the proliferation of the CD40(+) colon cancer cell lines. The inhibition could also be enhanced by IFN-gamma in HCT116 and SW48 cell lines. In addition, rshCD40L induced apoptosis of the CD40(+) colon cancer cell lines. Theses results suggest that CD40 present in colon cancer, and rshCD40L may be of clinical use to inhibit human colon cancer growth. (C) 2008 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
Article Cell Biology

Loss of B1 and marginal zone B cells during ovarian cancer

Jeffrey Maslanka, Gretel Torres, Jennifer Londregan, Naomi Goldman, Daniel Silberman, John Somerville, James E. Riggs

Summary: This study investigates the immunobiology of the peritoneum in ovarian cancer, revealing reduced B1 cells in the ascites and selective loss of B1 and marginal zone B cell subsets in the spleen. These findings suggest a correlation between the depletion of B cell subsets and the influx of myeloid-derived suppressor cells during ovarian cancer.

CELLULAR IMMUNOLOGY (2024)